3-V Biosciences Garners $28,500,000 Series D Round

  • Feed Type
  • Date
    12/31/2014
  • Company Name
    3-V Biosciences
  • Mailing Address
    1050 Hamilton Court Menlo Park, CA 94025 USA
  • Company Description
    3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich.
  • Website
    http://www.3vbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $28,500,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from this capital infusion enable the advancement of 3-V’s oncology clinical trials being performed as monotherapy and in combination with cytotoxic agents through phase IB expansion cohorts. The results obtained will bring 3-V to a value inflection point with a randomized phase II study being the potential next development milestone. In addition, the Company expects to conclude preclinical and IND-enabling work for the second program derived from their drug-discovery platform for regulatory (IND or CT) filing in 2015.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy